These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 18460853

  • 1. [Maintenance treatment by anti-tumor necrosis factor monoclonal antibody in Crohn's disease--long-term effects and safety].
    Matsui T.
    Nihon Shokakibyo Gakkai Zasshi; 2008 May; 105(5):649-58. PubMed ID: 18460853
    [No Abstract] [Full Text] [Related]

  • 2. Timing infliximab therapy in pediatric Crohn's disease.
    Kirschner BS, Huo D.
    Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
    [No Abstract] [Full Text] [Related]

  • 3. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 4. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M, Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives.
    Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [Abstract] [Full Text] [Related]

  • 5. [Indications and results of infliximab in Crohn's disease].
    Karoui S, Boubaker J, Filali A.
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [Abstract] [Full Text] [Related]

  • 6. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab.
    Moss AC, Treister NS, Marsee DK, Cheifetz AS.
    Gastroenterology; 2007 Feb; 132(2):488, 829. PubMed ID: 17261307
    [No Abstract] [Full Text] [Related]

  • 7. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M, Panes J, García V, Mañosa M, Esteve M, Merino O, Andreu M, Gutierrez A, Gomollón F, Cabriada JL, Montoro MA, Mendoza JL, Nos P, Gisbert JP.
    J Clin Gastroenterol; 2011 Feb; 45(2):113-8. PubMed ID: 21242747
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M, Karoui S, Meknini M, Matri S, Kallel L, Fekih M, Boubaker J, Filali A.
    Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
    [Abstract] [Full Text] [Related]

  • 9. Are we giving biologics too late? The case for early versus late use.
    Ricart E, García-Bosch O, Ordás I, Panés J.
    World J Gastroenterol; 2008 Sep 28; 14(36):5523-7. PubMed ID: 18810770
    [Abstract] [Full Text] [Related]

  • 10. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T.
    Aliment Pharmacol Ther; 2007 Apr 01; 25(7):787-96. PubMed ID: 17373917
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
    Cohen RD.
    Inflamm Bowel Dis; 2001 May 01; 7 Suppl 1():S17-22. PubMed ID: 11380038
    [Abstract] [Full Text] [Related]

  • 12. Maintenance infliximab infusions forever?
    Lee SD, Surawicz CM.
    Am J Gastroenterol; 2002 Nov 01; 97(11):2917-8. PubMed ID: 12425570
    [No Abstract] [Full Text] [Related]

  • 13. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S.
    Gastroenterology; 2015 Jun 01; 148(7):1320-9.e3. PubMed ID: 25724455
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy with infliximab and immunomodulators: is the glass half empty?
    Deshpande AR, Abreu MT.
    Gastroenterology; 2008 Jun 01; 134(7):2161-3. PubMed ID: 18482585
    [No Abstract] [Full Text] [Related]

  • 15. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L, Laclotte C, Bigard MA.
    Aliment Pharmacol Ther; 2007 Mar 15; 25(6):675-80. PubMed ID: 17311600
    [Abstract] [Full Text] [Related]

  • 16. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
    Loftus EV.
    Am J Gastroenterol; 2005 Jul 15; 100(7):1435-8. PubMed ID: 15984960
    [No Abstract] [Full Text] [Related]

  • 17. Monoclonal antibody therapy for Crohn's disease.
    Selby W.
    Intern Med J; 2001 Mar 15; 31(2):73-4. PubMed ID: 11480481
    [No Abstract] [Full Text] [Related]

  • 18. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J, Detlie TE, Vatn S, Ricanek P.
    Expert Rev Gastroenterol Hepatol; 2015 Mar 15; 9 Suppl 1():45-52. PubMed ID: 26395534
    [Abstract] [Full Text] [Related]

  • 19. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
    Lichtenstein GR.
    Am J Gastroenterol; 2005 Jul 15; 100(7):1433-5. PubMed ID: 15984959
    [No Abstract] [Full Text] [Related]

  • 20. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
    Carroccio A, Di Prima L, Pirrone G, Ambrosiano G, Noto D, Cefalù AB.
    Recenti Prog Med; 2006 Feb 15; 97(2):108-12; quiz 122. PubMed ID: 16671277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.